Medipron Receives MFDS Approval for In Vitro Diagnostic Medical Device Products
[Asia Economy Reporter Kum Boryeong] Mediphron announced on the 21st that it has received product approval from the Ministry of Food and Drug Safety for the in vitro diagnostic medical device 'QPLEXTM Alz plus assay,' which helps confirm the accumulation of beta-amyloid in the brain.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
Mediphron stated, "To detect amyloid in the brain, expensive imaging equipment called PET or cerebrospinal fluid tests via lumbar puncture have mainly been used, but both methods have raised concerns about high costs and potential side effects. The QPLEX™ Alz plus assay medical device, co-developed by Mediphron and Quantamatrix, requires only a small amount of blood for testing, and is expected to be significantly more affordable compared to PET, offering strong price competitiveness."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
